Gentis

About:

Gentis develops biomaterials-based products for the treatment of early-stage degeneration of the spine.

Top Investors: Easton Capital, Ivy Capital, Pappas Ventures, Matignon Investissement & Gestion, Matignon Technologies

Description:

Gentis is a developer of minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spine. The company's patented product is DiscCell, an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material that augments or replaces the diseased nucleus pulposus of the spinal disc. Gentis was founded on 2000 and is headquartered in Wayne, Pennsylvania.

Total Funding Amount:

$10.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Wayne, Pennsylvania, United States

Founded Date:

2000-01-01

Contact Email:

info(AT)gentisinc.com

Founders:

Charles Cohen, Paul Ducheyne

Number of Employees:

11-50

Last Funding Date:

2010-07-19

IPO Status:

Private

Industries: